HIF1A and pancreatic neoplasm: demonstrated that in pancreatic cancer cells, MUC1’s interaction with HIF-1α promotes glycolysis, leading to increased dCTP levels and decreased gemcitabine efficacy, while targeting HIF-1α markedly reduces tumor burden, underscoring MUC1’s essential role (61).